Transarterial Chemoembolization for the Treatment of Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial evaluates how well transarterial chemoembolization (TACE) works in
treating patients with non-small cell lung cancer. TACE involves the injection of a blocking
agent (tris-acryl gelatin microspheres [embospheres]) and a chemotherapy agent (mitomycin)
directly into the artery that supplies oxygen to lung tumors. Mitomycin works by inhibiting
deoxyribonucleic acid synthesis. At the same time, the artery is blocked (embolized) with a
blocking agent called tris-acryl gelatin microspheres (embospheres). This traps the
chemotherapy inside the tumor and also cuts off the tumor's blood supply. As a result, the
tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and
oxygen. An imaging agent called ethiodized oil (lipiodol) is also used during the procedure
for help visualizing the tumor. TACE with mitomycin, lipiodol, and embospheres may be
effective at controlling or stopping the growth of lung tumors.